Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valacyclovir vs Valganciclovir for CMV Prophylaxis in Kidney Transplant
NCT01972035Phase 2Completed
- Sponsor
- University of Minnesota
- Start
- Aug 2014
- Primary completion
- Feb 2021
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of valaciclovir in cytomegalovirus infection (CMV) and Epstein-Barr virus infection (2 arms), sponsored by University of Minnesota. Primary endpoint: Incidence, Duration and Magnitude of CMV and EBV Viremia at 1 year. Started Aug 2014; status: completed.
02
Drugs
valaciclovir
03
Conditions
cytomegalovirus infection (CMV)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT01972035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01972035.